Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 97
Filter
1.
An. bras. dermatol ; 95(2): 207-209, Mar.-Apr. 2020. graf
Article in English | ColecionaSUS, LILACS, ColecionaSUS | ID: biblio-1130852

ABSTRACT

Abstract Infantile hemangioma is the most common pediatric vascular tumor, with the following risk factors: low birth weight, prematurity, white skin, female gender, multiparity and advanced maternal age. The use of oral and topical beta-blockers, although recent, has emerged as the first line of treatment, with superior safety and efficacy to previously used therapies, such as corticosteroids and surgeries. This report describes two cases of nasal tip infantile hemangioma, treated with oral propranolol. Both presented excellent therapeutic responses.


Subject(s)
Humans , Female , Infant , Propranolol/administration & dosage , Nose Neoplasms/drug therapy , Adrenergic beta-Antagonists/administration & dosage , Hemangioma/drug therapy , Nose Neoplasms/pathology , Administration, Oral , Treatment Outcome , Hemangioma/pathology
2.
Ciênc. Saúde Colet ; 24(1): 67-75, ene. 2019. tab, graf
Article in Portuguese | LILACS | ID: biblio-974802

ABSTRACT

Resumo Queda recorrente representa alto risco de morbidade e mortalidade em idosos, principalmente institucionalizados, dado ao seu quadro de fragilidade e declínio funcional evidentes. O objetivo deste estudo é determinar a incidência e os fatores de risco relacionados a quedas recorrentes em idosos institucionalizados. Estudo longitudinal tipo coorte no período de um ano. Foram avaliados indivíduos com 60 anos ou mais residentes em 10 Instituições de Longa Permanência para Idosos, que deambulassem e possuíssem capacidade cognitiva preservada. Foi questionada a ocorrência de quedas nos últimos doze meses, considerando recorrentes a ocorrência de dois ou mais episódios neste período. Foram ainda coletadas variáveis referentes à instituição, condições sócio demográficas e de saúde do idoso através de questionários. Do total de 364 idosos, 130 foram incluídos. A incidência de quedas recorrentes foi de 26.9% (IC 95% = 22.4 - 31.5). A partir do Qui-quadrado e Regressão Logística, considerando o nível de significância de 5%, foi encontrada fadiga como fator de risco (p = 0.001; RR = 2.9) e uso de betabloqueadores como fator de proteção (p = 0.010; RR = 0.1). Conclui-se que queda recorrente é comum nas Instituições de Longa Permanência para Idosos e a fadiga representa fator de risco.


Abstract Recurrent falls constitute a high risk for morbidity and mortality among older people, especially institutionalized individuals, due to greater frailty and functional decline in this group. The aim of this study was to identify risk factors associated with recurrent falls among institutionalized older persons. A longitudinal cohort study was conducted over a one-year period with a study sample consisting of individuals aged 60 years and over living in 10 Nursing homes (NH) who were able to walk and had preserved cognitive ability. The older persons and carers were asked about the occurrence of falls over the last twelve months. The older persons were considered recurrent fallers if they had had two or more falls during this period. Institutional, sociodemographic and health data was also collected using questionnaires and the residents' medical records. One hundred and thirty individuals were included in the sample out of a total of 364 older people living in the NH. The incidence of recurrent falls was 26.9% (CI95% = 22.4 - 31.5). The results of the chi-square test and logistic regression adopting a significance level of 0.05 showed that fatigue was a risk factor for recurrent falls(p = 0.001; RR = 2.9) and that the use of beta blockers was a protective factor (p = 0.010; RR = 0.1). It was concluded that recurrent falls are common in NH and that fatigue constitutes an important risk factor.


Subject(s)
Humans , Male , Female , Aged , Aged, 80 and over , Accidental Falls/statistics & numerical data , Fatigue/epidemiology , Frailty/epidemiology , Nursing Homes/statistics & numerical data , Recurrence , Logistic Models , Incidence , Surveys and Questionnaires , Risk Factors , Cohort Studies , Longitudinal Studies , Adrenergic beta-Antagonists/administration & dosage , Protective Factors , Middle Aged
3.
Arq. gastroenterol ; 53(4): 257-261, Oct.-Dec. 2016. tab, graf
Article in English | LILACS | ID: lil-794600

ABSTRACT

ABSTRACT Background The efficacy of nonselective β-blocker and endoscopic procedures, such as endoscopic variceal ligation, as primary prophylaxis of variceal hemorrhage in cirrhotic adults was demonstrated by numerous controlled trials, but in pediatric population, few are the number of studies. Objective The objective of this study is to evaluate the primary prophylaxis with β-blocker in cirrhotic children and adolescents with portal hypertension. Methods This is a cohort study encompassing 26 cirrhotic patients. β-blocker prophylaxis was performed with propranolol. When contraindicated the use of β-blocker, or if side effects presents, the patients were referred to endoscopic therapy with band ligation. Patients were evaluated by endoscopy, and those who had varicose veins of medium and large caliber or reddish spots, regardless of the caliber of varices, received primary prophylaxis. Results Of the 26 patients evaluated, 9 (34.6%) had contraindications to the use of propranolol and were referred for endoscopic prophylaxis. Six (35.3%) of the 17 patients who received β-blocker (propranolol), had bled after a median follow-up time of 1.9 years. β-blockage dosage varied from 1 mg/kg/day to 3.1 mg/kg/day and seven (41.2%) patients had the propranolol suspended due to fail of the β-blockage or adverse effects, such as drowsiness, bronchospasm and hypotension. Patients who received endoscopic prophylaxis (elastic bandage) had no bleeding during the follow-up period. Conclusion All of the patients that had upper gastroinstestinal bleeding in this study were under propranolol prophylaxis. The use of propranolol showed a high number of contraindications and side effects, requiring referral to endoscopic prophylaxis. The endoscopic prophylaxis was effective in reducing episodes of bleeding.


RESUMO Contexto A eficácia dos beta-bloqueadores e de procedimentos endoscópicos como a ligadura elástica endoscópica para profilaxia primária de ruptura de varizes de esôfago em adultos cirróticos já foram demonstrados por inúmeros ensaios clínicos na população adulta, porém poucos são os estudos envolvendo a faixa etária pediátrica. Objetivo Avaliar a profilaxia primária com β-bloqueador em crianças e adolescentes cirróticos com hipertensão porta. Métodos Estudo de coorte envolvendo 26 pacientes cirróticos. O propranolol foi o β-bloqueador utilizado para a profilaxia. Quando contraindicado o uso de β-bloqueador, ou se efeitos colaterais presentes, os pacientes eram encaminhados para profilaxia endoscópica com ligadura elástica. Os pacientes foram avaliados por endoscopia, e naqueles que foram observadas varizes de médio e/ou grosso calibre ou presença de manchas avermelhadas nas varizes, independentemente do calibre das varizes, a profilaxia primária foi indicada. Resultados Dos 26 pacientes avaliados, 9 (34,6%) tinham contraindicações para o uso de propranolol e foram encaminhados para a profilaxia endoscópica. Seis (35,3%) dos 17 pacientes que receberam β-bloqueador (propranolol) apresentaram sangramento após mediana de tempo de acompanhamento de 1,9 anos. A dose de β-bloqueio variou de 1 mg/kg/dia a 3,1mg/kg/dia e em sete (41,2%) pacientes o propranolol foi suspenso por falha em atingir β-bloqueio ou presença de efeitos adversos, tais como sonolência, broncoespasmo e hipotensão. No grupo de pacientes que receberam a profilaxia endoscópica (ligadura elástica) não foi observado nenhum episódio de hemorragia digestiva alta durante o período de acompanhamento. Conclusão Todos os pacientes que apresentaram hemorragia digestiva alta no presente estudo estavam recebendo profilaxia com propranolol. Foi observado, ainda, elevado número de contraindicações e efeitos colaterais, com consequente encaminhamento para profilaxia endoscópica. A profilaxia endoscópica foi eficaz na redução de episódios de hemorragia digestiva alta.


Subject(s)
Humans , Male , Female , Infant , Child, Preschool , Child , Adolescent , Primary Prevention/methods , Propranolol/administration & dosage , Esophageal and Gastric Varices/prevention & control , Endoscopy, Gastrointestinal , Adrenergic beta-Antagonists/administration & dosage , Gastrointestinal Hemorrhage/chemically induced , Gastrointestinal Hemorrhage/prevention & control , Hypertension, Portal/etiology , Liver Cirrhosis/complications , Cohort Studies , Treatment Outcome , Contraindications , Ligation/methods
4.
Clinics ; 71(11): 635-638, Nov. 2016. tab
Article in English | LILACS | ID: biblio-828550

ABSTRACT

OBJECTIVES: Recent studies have revealed a relationship between beta-blocker use and worse prognosis in acute coronary syndrome, mainly due to a higher incidence of cardiogenic shock. However, the relevance of this relationship in the reperfusion era is unknown. The aim of this study was to analyze the outcomes of patients with acute coronary syndrome that started oral beta-blockers within the first 24 hours of hospital admission (group I) compared to patients who did not use oral beta-blockers in this timeframe (group II). METHODS: This was an observational, retrospective and multicentric study with 2,553 patients (2,212 in group I and 341 in group II). Data regarding demographic characteristics, coronary treatment and medication use in the hospital were obtained. The primary endpoint was in-hospital all-cause mortality. The groups were compared by ANOVA and the chi-square test. Multivariate analysis was conducted by logistic regression and results were considered significant when p<0.05. RESULTS: Significant differences were observed between the groups in the use of angiotensin-converting enzyme inhibitors, enoxaparin, and statins; creatinine levels; ejection fraction; tabagism; age; and previous coronary artery bypass graft. Significant differences were also observed between the groups in mortality (2.67% vs 9.09%, OR=0.35, p=0.02) and major adverse cardiovascular events (11% vs 29.5%, OR=4.55, p=0.02). CONCLUSIONS: Patients with acute coronary syndrome who underwent early intervention with oral beta-blockers during the first 24 hours of hospital admission had a lower in-hospital death rate and experienced fewer major adverse cardiovascular events with no increase in cardiogenic shock or sustained ventricular arrhythmias compared to patients who did not receive oral beta-blockers within this timeframe.


Subject(s)
Humans , Male , Female , Middle Aged , Aged , Acute Coronary Syndrome/drug therapy , Acute Coronary Syndrome/mortality , Adrenergic beta-Antagonists/administration & dosage , Myocardial Infarction/drug therapy , Brazil/epidemiology , Hospital Mortality , Logistic Models , Multivariate Analysis , Myocardial Infarction/mortality , Retrospective Studies , Shock, Cardiogenic/mortality , Treatment Outcome
5.
Brasília; CONITEC; maio 2016. tab, ilus, ilus.
Monography in Portuguese | LILACS, BRISA | ID: biblio-837341

ABSTRACT

Contexto: A insuficiência cardíaca crônica é uma síndrome sistêmica complexa e progressiva que se caracteriza por comprometimento da perfusão tecidual, com sintomas característicos de dispneia, fadiga, além de piora da qualidade de vida. A síndrome está relacionada a altas taxas de mortalidade e hospitalização. Ivabradina é um protótipo de medicamentos que agem na frequência cardíaca e que recentemente foi aprovada para tratamento de insuficiência cardíaca crônica associada a betabloqueadores em indivíduos em estágios mais avançados da doença e que mantêm a frequência cardíaca alta mesmo em tratamento com as doses mais altas toleradas desses medicamentos. Pergunta: A associação de ivabradina ao tratamento convencional com betabloqueadores é eficaz e segura no tratamento de pacientes com insuficiência cardíaca crônica, quando comparada ao tratamento com betabloqueadores? Evidências científicas: Foram avaliados 15 estudos, dentre os quais um ensaio clínico duplo-cego, randomizado e controlado por placebo no qual se incluíram 6.500 indivíduos com insuficiência cardíaca crônica em estágio funcional NYHA II a IV e frequência cardíaca ≥70 bpm. O tratamento com ivabradina em dose média de 6 mg duas vezes ao dia em associação a betabloqueadores por 23 meses diminuiu o risco de internação por piora no quadro de insuficiência cardíaca em 26%, ao que se associa um NNT de 20 (IC 95% 15 a 31). O medicamento não demonstrou efeito no desfecho primário mortalidade por causas cardiovasculares como também não se observou diminuição de risco de mortalidade por todas as causas. Observou-se uma diminuição no risco de mortalidade por insuficiência cardíaca, desfecho secundário, embora associada à imprecisão importante, em função das baixas taxas de eventos e do amplo intervalo de confiança (NNT 83, IC 95% 52 a 333). Por meio de outros estudos sugere-se que o medicamento tenha efeitos na reversão do remodelamento cardíaco associada à progressividade da doença, diminuição de biomarcadores relacionados à insuficiência cardíaca e na diminuição da pós-carga cardíaca, melhorando o funcionamento ventricular e acoplamento ventrículo arterial, sem, entretanto, interferir na função renal. Identificaram-se efeitos na diminuição da frequência cardíaca e da variação da frequência cardíaca. O uso do medicamento está associado a um NNH de 58 (no período de dois anos) em relação ao desfecho fibrilação atrial em indivíduos com frequência cardíaca maior que 70 bpm. Discussão: O principal benefício do medicamento, cujo efeito foi avaliado por meio de evidência de alta qualidade, é evitar internações por piora no quadro de insuficiência cardíaca. O efeito relativo é de uma diminuição de 26% quando se compara ao uso isolado de betabloqueadores. Entretanto, mesmo para o desfecho de maior benefício, o efeito absoluto ainda é muito baixo, atingindo uma diminuição de 4,9% apenas. Para outros desfechos de hospitalização, o efeito absoluto é ainda mais baixo e mais impreciso. Não houve efeito na mortalidade de forma que o uso do medicamento não obteve efeito nos desfechos mortalidade por todas as causas e por causas cardiovasculares. O efeito estatisticamente significativo observado para diminuição em mortalidade por insuficiência cardíaca partiu de uma medida de baixa qualidade e, portanto, um efeito de baixa confiabilidade e bastante passível de modificação por trabalhos futuros. O medicamento aumenta o risco de fibrilação atrial, como um NNH de 83. Os resultados da análise econômica são frágeis e partem de informações imprecisas, principalmente sobre a estimativa, em termos quantitativos, da população elegível ao tratamento com ivabradina. Decisão: Não incorporar a ivabradina para o tratamento de insuficiência cardíaca crônica moderada a grave em indivíduos com frequência cardíaca ≥ 70 bpm e que toleram menos de 50% da dose alvo recomendada de agentes betabloqueadores, no âmbito do Sistema Único de Saúde - SUS. Foi publicada a Portaria Nº 19, de 24 de maio de 2016.


Subject(s)
Humans , Adrenergic beta-Antagonists/administration & dosage , Benzazepines/therapeutic use , Heart Failure/drug therapy , Heart Rate/drug effects , Brazil , Cost-Benefit Analysis/economics , Technology Assessment, Biomedical , Unified Health System
6.
Int. j. cardiovasc. sci. (Impr.) ; 29(2): 118-127, mar.-abr. 2016. tab
Article in English, Portuguese | LILACS | ID: biblio-831102

ABSTRACT

Fundamentos: Metade dos pacientes com fração de ejeção reduzida tem disfunção diastólica associada e os dados relacionados ao impacto da terapia com carvedilol nesses pacientes ainda são conflitantes.Objetivo: Avaliar o comportamento dos índices ecocardiográficos, cintilográficos e do volume do átrio esquerdo(VAE) antes e após três meses de terapia com carvedilol em pacientes com ICFER, classe funcional (CF) II e III da New York Heart Association (NYHA).Métodos: Selecionados 19 pacientes com IC, CF II e III, fração de ejeção <45% (método de Simpson) e sem terapiaprévia com carvedilol. Para análise estatística, utilizados os testes de Wilcoxon e McNemar, coeficiente de Spearmane regressão linear múltipla. Resultados: Houve melhora significativa dos parâmetros de função sistólica do ventrículo esquerdo (VE): DSF,VSF, FEJ Simpson, FEVI. Não houve melhora significativa dos parâmetros de função diastólica derivados do Doppler: E’, E/E’, VP, E/VP. O comportamento da função diastólica através VAE apresentou significativa melhora:VAE (83,2±33,4mL vs. 73,7±29,8mL, p=0,009), índice de VAE (44,8±15,8mL/m² vs. 39,7±14,5mL/m², p=0,014). Conclusões: A regressão do VAE após terapia em curto prazo com carvedilol não se associou à melhora dos demais índices de função diastólica, entretanto houve associação com a melhora da função sistólica do VE. Estes achados sugerem que a redução do VAE seja secundária à melhora da performance sistólica.


Background: Half of the patients with reduced ejection fraction have diastolic dysfunction associated and the data related to the impact of carvedilol therapy in these patients are still conflicting.Objective: To evaluate the behavior of echocardiographic, scintigraphic and left atrial volume (LAV) indexes before and after three months of therapy with carvedilol in patients with HFREF, New York Heart Association (NYHA) functional class (FC) II and III. Methods: Nineteen patients with HF, CF II and III, ejection fraction <45% (Simpson method) without previous therapy with carvedilol were selected. For statistical analysis, Wilcoxon and McNemar tests, Spearman coefficient and multiple linear regression were used. Results: There was significant improvement in the left ventricular (LV) systolic function parameters: DSF, ESV, Simpson EF,EFVI. There was no significant improvement in the diastolic function parameters derived from Doppler: E’, E/E’, VP, E/VP. Diastolic function behavior through VAE showed significant improvement: LAV (83.2±33.4 mL vs. 73.7±29.8 mL, p=0.009), LAV index(44.8±15.8mL/m2 vs. 39.7±14.5mL/m2, p=0.014). Conclusions: LAV regression after short-term therapy with carvedilol was not associated with improvement in other diastolic function indexes, but was associated with improved LV systolic function. These findings suggest that LAV reduction is secondary to improvement in systolic performance.


Subject(s)
Humans , Male , Female , Adrenergic beta-Antagonists/administration & dosage , Radionuclide Imaging/methods , Echocardiography/methods , Heart Atria , Heart Failure/complications , Heart Failure/epidemiology , Patients , Brazil/epidemiology , Multivariate Analysis , Drug Therapy/methods , Stroke Volume , Treatment Outcome
7.
Braz. j. med. biol. res ; 49(3): e5011, Mar. 2016. graf
Article in English | LILACS | ID: lil-771943

ABSTRACT

There is evidence for participation of peripheral β-adrenoceptors in delayed liquid gastric emptying (GE) induced in rats by dipyrone (Dp), 4-aminoantipyrine (AA), and antipyrine (At). The present study aimed to determine whether β-adrenoceptors are involved in delayed GE induced by phenylpyrazole derivatives and the role of the prevertebral sympathetic nervous system in this condition. Male Wistar rats weighing 220-280 g were used in the study. In the first experiment rats were intravenously pretreated with vehicle (V), atenolol 30 mg/kg (ATE, β1-adrenergic antagonist), or butoxamine 25 mg/kg (BUT, β2-adrenergic antagonist). In the second experiment, rats were pretreated with V or SR59230A 2 mg/kg (SRA, β3-adrenergic antagonist). In the third experiment, rats were subjected to surgical resection of the celiac-superior mesenteric ganglion complex or to sham surgery. The groups were intravenously treated with saline (S), 240 µmol/kg Dp, AA, or At, 15 min after pretreatment with the antagonists or V and nine days after surgery. GE was determined 10 min later by measuring the percentage of gastric retention (%GR) of saline labeled with phenol red 10 min after gavage. The %GR (means±SE, n=6) values indicated that BUT abolished the effect of Dp (BUT+Dp vs V+Dp: 35.0%±5.1% vs 56.4%±2.7%) and At (BUT+At vs V+At: 33.5%±4.7% vs 52.9%±2.6%) on GE, and significantly reduced (P<0.05) the effect of AA (BUT+AA vs V+AA: 48.0%±5.0% vs 65.2%±3.8%). ATE, SRA, and sympathectomy did not modify the effects of treatments. These results suggest that β2-adrenoceptor activation occurred in delayed liquid gastric emptying induced by the phenylpyrazole derivatives dipyrone, 4-aminoantipyrine, and antipyrine. Additionally, the released neurotransmitter did not originate in the celiac-superior mesenteric ganglion complex.


Subject(s)
Animals , Male , Adrenergic beta-Antagonists/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Antipyrine/administration & dosage , Ganglionectomy , Gastric Emptying/drug effects , Receptors, Adrenergic, beta/metabolism , Adrenergic beta-Antagonists/administration & dosage , Ampyrone/pharmacology , Atenolol/pharmacology , Butoxamine/pharmacology , Dipyrone/pharmacology , Dose-Response Relationship, Drug , Ganglia, Sympathetic/surgery , Models, Animal , Propanolamines/pharmacology , Rats, Wistar , Sympathetic Nervous System/drug effects
8.
Yonsei Medical Journal ; : 1114-1121, 2015.
Article in English | WPRIM | ID: wpr-150471

ABSTRACT

PURPOSE: The aim of this study was to evaluate the effects of premedication with oral atenolol or enalapril, in combination with remifentanil under sevoflurane anesthesia, on intraoperative blood loss by achieving adequate deliberate hypotension (DH) during orthognathic surgery. Furthermore, we investigated the impact thereof on the amount of nitroglycerin (NTG) administered as an adjuvant agent. MATERIALS AND METHODS: Seventy-three patients undergoing orthognathic surgery were randomly allocated into one of three groups: an angiotensin converting enzyme inhibitor group (Group A, n=24) with enalapril 10 mg, a beta blocker group (Group B, n=24) with atenolol 25 mg, or a control group (Group C, n=25) with placebo. All patients were premedicated orally 1 h before the induction of anesthesia. NTG was the only adjuvant agent used to achieve DH when mean arterial blood pressure (MAP) was not controlled, despite the administration of the maximum remifentanil dose (0.3 microg kg-1min-1) with sevoflurane. RESULTS: Seventy-two patients completed the study. Blood loss was significantly reduced in Group A, compared to Group C (adjusted p=0.045). Over the target range of MAP percentage during DH was significantly higher in Group C than in Groups A and B (adjusted p-values=0.007 and 0.006, respectively). The total amount of NTG administered was significantly less in Group A than Group C (adjusted p=0.015). CONCLUSION: Premedication with enalapril (10 mg) combined with remifentanil under sevoflurane anesthesia attenuated blood loss and achieved satisfactory DH during orthognathic surgery. Furthermore, the amount of NTG was reduced during the surgery.


Subject(s)
Administration, Oral , Adrenergic beta-Antagonists/administration & dosage , Adult , Aged , Anesthesia, Inhalation , Atenolol/administration & dosage , Blood Loss, Surgical , Blood Pressure/drug effects , Cardiac Output/drug effects , Double-Blind Method , Enalapril/administration & dosage , Female , Heart Rate/drug effects , Humans , Intraoperative Care , Male , Methyl Ethers/administration & dosage , Middle Aged , Orthognathic Surgical Procedures , Piperidines/administration & dosage , Premedication , Treatment Outcome
9.
Article in English | IMSEAR | ID: sea-162144

ABSTRACT

Aims: Despite well developed guidelines in the management of ST elevation myocardial infarction with low left ventricular ejection fraction, β-blockers remain an underutilized therapy. We aim to assess the adherence of β-blocker use during the discharge in Shahid Gangalal National Heart Centre, Kathmandu, Nepal. Study Design: Retrospective, Observational study. Place and Duration of Study: Department of cardiology, Shahid Gangalal National Heart Centre, Kathmandu, Nepal. Between January 2012 to December 2012. Methodology: Medical records of 160ST elevation myocardial infarction patients with left ventricular ejection fraction ≤40% and discharged from our centre were retrospectively reviewed regarding the use of β-blocker. Results: Among the 160 patients, 112 (70%) were males and 48 (30%) were females, mean age was 59.1±13.4 years. Anterior wall myocardial infarction followed by extensive anterior wall was the common in patient with low left ventricular ejection fraction after ST elevation myocardial infarction. Only in 67.5% patients β-blockers were prescribed. Metoprolol tartrate was the most commonly used β-blocker. Conclusion: β-blocker use in patients ST elevation myocardial infarction patients with low left ventricular ejection fraction in our study is comparable to international studies. We still need some more effort to improve our prescription rate.


Subject(s)
Adrenergic beta-Antagonists/administration & dosage , Adrenergic beta-Antagonists/therapeutic use , Aged , Electrocardiography , Female , Guidelines as Topic , Humans , Male , Myocardial Infarction/drug therapy , Myocardial Infarction/epidemiology , Myocardial Infarction/physiopathology , Middle Aged , Nepal , Retrospective Studies , Stroke Volume , Ventricular Dysfunction, Left/epidemiology , Ventricular Dysfunction, Left/physiology
10.
Bogotá; IETS; jul. 2014. tab, ilus.
Monography in Spanish | LILACS, BRISA | ID: biblio-847225

ABSTRACT

Introducción: La HTA es una enfermedad crónica caracterizada por un aumento sostenido en los niveles de la TA normal. La cronicidad de la HTA afecta otras estructuras anatómicas siendo un factor de riesgo para el desarrollo de varias enfermedades. Sin embargo, a pesar de contar con varias opciones terapéuticas, determinar su efectividad comparativa y escoger la terapia antihipertensiva es difícil, ya que la selección de ésta puede estar influenciado por muchas variables y por la amplia gama de terapia que está disponible. Objetivo: Evaluar la efectividad y seguridad de fármacos bloqueadores de los receptores beta adrenérgicos, comparados entre sí para el tratamiento de pacientes con HTA y insuficiencia cardiaca concomitante. Metodología: se realizó una evaluación crítica a través de una búsqueda sistemática en bases de datos electrónicas, diseñadas con vocabulario controlado y no controlado, además, de indagar con expertos sobre la disponibilidad de estudios publicados y no publicados, en inglés y español, la tamización de los resultados fue llevada a cabo por 2 revisores expertos. Los hallazgos de efectividad y seguridad fueron extraídos de los estudios con mejor calidad metodológica, buscando obtener información para todas las comparaciones y desenlaces de interés. Resultados: En la evidencia encontrada no se hallaron diferencias estadísticamente significativas para los cambios de FrC, TAS y TAD pero si para mortalidad, favoreciendo a carvedilol sobre metoprolol (HR 0.71, IC 95 0.56-0.90). Conclusiones: No hay diferencias entre BB para la FrC, TAS y TAD. Para mortalidad carvedilol es más efectivo que metoprolol. Seguridad: No hay diferencias en cuanto a nebivolol versus carvedilol en cuanto eventos adversos. No se encontró evidencia para otras comparaciones.(AU)


Subject(s)
Humans , Adrenergic beta-Antagonists/administration & dosage , Heart Failure/drug therapy , Hypertension/drug therapy , Colombia , Technology Assessment, Biomedical , Treatment Outcome
11.
Medicina (B.Aires) ; 74(2): 99-103, abr. 2014. tab
Article in Spanish | LILACS | ID: lil-708588

ABSTRACT

Se comparó la adherencia a la prevención secundaria de enfermedad coronaria mediante el uso indicado de fármacos de probada eficacia, al momento del egreso hospitalario y a 3 años de seguimiento, en una cohorte de pacientes afiliados al Plan de Salud del Hospital Italiano. Se realizó un estudio de cohorte retrospectivo que incluyo 125 pacientes menores de 80 años de edad, afiliados a una red integrada de salud, con internación por síndrome coronario agudo. En el análisis se utilizó el test de McNemar. La edad media de los participantes fue 63.7 años (DS 10.08) y el 65.6% (IC95% 56.6-73.9) fue de sexo masculino. El 76.8% (IC95% 68.4-83.9) presentó como evento calificante un síndrome coronario agudo sin elevación del segmento ST. El tiempo de seguimiento promedio fue 2.94 años (DS 0.25). Se observó que el uso de drogas de probada eficacia en la prevención secundaria de enfermedad coronaria descendió entre el momento del egreso hospitalario y los 3 años de seguimiento: antiagregantes de 97.6 a 88.0% (p = 0.012); beta-bloqueantes de 94.4 a 84.8% (p = 0.021); estatinas 91.2 a 83.7% (p = 0.035). Uso combinado de antiagregantes, betabloqueantes y estatinas de 86.4 a 66.3% (p < 0.0001). Es necesario estudiar las causas de la disminución de la adherencia a drogas cardioprotectoras a largo plazo.


We compared the use of evidence-based secondary prevention drugs for coronary artery disease at hospital discharge and 3 years of follow-up in a group of patients associated to an integrated network of health services. We conducted a retrospective group study that included 125 patients under 80 years of age who were hospitalized for acute coronary syndrome. McNemar´s test was used to compare values at baseline and 3 years. The mean age of of participants was 63.7 years (SD ± 10.08) and 65.6% (95% CI 56.6-73.9) of male sex. The average follow-up time was 2.94 years (SD ± 0.25). The use of secondary prevention drugs for coronary heart disease decreased at 3 years of follow-up: anti-platelet 97.6 to 88.0% (p = 0.012), beta-blockers 94.4 to 84.8% (p = 0.021) and statins 83.7 to 91.2% (p = 0.035). Patients medicated with a combination of anti-platelet, beta blockers and statins showed a decrease from 86.4 to 66.3% (p < 0.0001). It is necessary to study the causes for the decreased adherence to long-term cardio-protective drugs.


Subject(s)
Aged , Female , Humans , Male , Middle Aged , Acute Coronary Syndrome/prevention & control , Medication Adherence , Secondary Prevention , Acute Coronary Syndrome/drug therapy , Adrenergic beta-Antagonists/administration & dosage , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Cohort Studies , Drug Therapy, Combination , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Platelet Aggregation Inhibitors/administration & dosage , Retrospective Studies
12.
Rev. Soc. Cardiol. Estado de Säo Paulo ; 24(1): 23-32, jan.-mar. 2014.
Article in Portuguese | SES-SP, LILACS, SES-SP, SESSP-IDPCPROD, SES-SP | ID: lil-729290

ABSTRACT

A elevada prevalência populacional de doença arterial coronária crônica propiciou a melhora dos métodos preventivos, diagnósticos e terapêuticos. A confirmação de isquemia, com ou sem sintomas, trouxe tratamento inovadores visando à redução de eventos agudos, melhora na qualidade de vida e aumento de sobrevida Estudos recentes comparam os resultados do tratamento clínico com outras intervenções e concluíram que o sucesso da intervenção clínica está embasado na otimização terapêutica. Definida a influência dos fatores de risco e os mecanismos fisiopatológicos da doença, o tratamento medicamentoso constitui a base e a sequência de todas as intervenções na doença arterial coronária crônica.


The high prevalence of patients with chronic coronary artery disease has led to the improvement of preventive, diagnostic and therapeutic methods. Confirmation of ischemia with or without symptoms, brought innovative treatment aimed at reducing acute events, improvement in quality of life and increased survival. Recent studies have compared the results of clinical treatment with other interventions and concluded that the success of clinical intervention is based on therapeutic optimization. Once established the inluence of risk factors and physiopathological mechanisms of the disease, drug treatment constitutes the basis and the sequence of all interventionns in chronic artery disease.


Subject(s)
Humans , Male , Female , Aspirin/administration & dosage , Coronary Artery Disease/physiopathology , Coronary Artery Disease/therapy , Myocardial Infarction/therapy , Heart Failure/physiopathology , Heart Failure/therapy , Drug Utilization/trends , Adrenergic beta-Antagonists/administration & dosage , Adrenergic beta-Antagonists/adverse effects , Calcium Channel Blockers/therapeutic use , Platelet Aggregation Inhibitors/administration & dosage , Angiotensin-Converting Enzyme Inhibitors/adverse effects , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage , Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects , Nitrates/therapeutic use , Trimetazidine/therapeutic use , Vasodilator Agents/therapeutic use
13.
Arq. bras. cardiol ; 101(5): 442-448, nov. 2013. ilus, tab
Article in Portuguese | LILACS | ID: lil-696887

ABSTRACT

FUNDAMENTO: A Insuficiência Cardíaca (IC) é uma síndrome que cursa com má evolução nas formas avançadas. O bloqueio neuro-hormonal modifica essa história natural; no entanto, ele com frequência é subotimizado. OBJETIVO: Neste estudo procuramos verificar em qual percentual médicos cardiologistas habituados no tratamento da IC conseguem prescrever as doses-alvo dos medicamentos de comprovada eficácia. MÉTODOS: Foram selecionados consecutivamente 104 pacientes ambulatoriais com disfunção sistólica, todos sob tratamento estabilizado. Avaliaram-se dados demográficos e o tratamento verificando-se as doses atingidas. Os achados são apresentados em percentual e fizeram-se correlações entre as diferentes variáveis. RESULTADOS: A idade média dos pac. foi de 64,1 ± 14,2 anos, com PAS 115,4 ± 15,3 mmHg, FC de 67,8 ± 9,4 bpm, peso 76,0 ± 17,0 kg e em ritmo sinusal (90,4%). Quanto ao tratamento, 93,3% estavam recebendo um bloqueador do SRA (52,9% IECA), todos recebiam betabloqueador (BB), sendo o carvedilol o mais prescrito (92,3%). Quanto às doses: 97,1% dos que recebiam um BRA estavam com dose abaixo da ideal; os que recebiam IECA 52,7% receberam dose otimizada. Quanto ao BB, em 76,0% foi possível prescrever as doses alvos. Nesse grupo de pac. a maioria com dose alvo do BB, pode-se observar que 36,5% apresentavam frequência cardíaca igual ou maior que 70 bpm em ritmo sinusal. CONCLUSÕES: Médicos cardiologistas habituados no tratamento da IC conseguem prescrever as doses-alvo de inibidores da ECA e BB para a maioria dos pac. Mesmo recebendo as doses preconizadas, cerca de um terço dos pac. persiste com FC acima de 70 bpm e deveria ter seu tratamento otimizado.


BACKGROUND: Heart failure (HF) is a syndrome that leads to poor outcome in advanced forms. The neurohormonal blockade modifies this natural history; however, it is often suboptimal. OBJECTIVE: The aim of this study is to assess at what percentage cardiologists used to treating HF can prescribe target doses of drugs of proven efficacy. METHODS: A total of 104 outpatients with systolic dysfunction were consecutively enrolled, all under stabilized treatment. Demographic and treatment data were evaluated and the doses achieved were verified. The findings are shown as percentages and correlations are made between different variables. RESULTS: The mean age of patients was 64.1 ± 14.2 years, with SBP =115.4 ± 15.3, HR = 67.8 ± 9.4 bpm, weight = 76.0 ± 17.0 kg and sinus rhythm (90.4%). As for treatment, 93.3% received a RAS blocker (ACEI 52.9%), all received beta-blockers (BB), the most often prescribed being carvedilol (92.3%). As for the doses: 97.1% of those receiving an ARB were below the optimal dose and of those who received ACEI, 52.7% received an optimized dose. As for the BB, target doses were prescribed to 76.0% of them. In this group of patients, most with BB target dose, it can be seen that 36.5% had HR > 70 bpm in sinus rhythm. CONCLUSION: Cardiologists used to treating HF can prescribe target doses of ACEI and BB to most patients. Even though they receive the recommended doses, about one third of patients persists with HR > 70 bpm and should have their treatment optimized.


Subject(s)
Aged , Female , Humans , Male , Middle Aged , Adrenergic beta-Antagonists/administration & dosage , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Heart Failure, Systolic/drug therapy , Heart Rate/drug effects , Chronic Disease , Cohort Studies , Cross-Sectional Studies , Outpatients , Statistics, Nonparametric
14.
Rev. chil. cir ; 65(3): 267-270, jun. 2013.
Article in Spanish | LILACS | ID: lil-684039

ABSTRACT

The proportion of older hypertensive patients that require a surgical procedure has increased in the last years. These patients require a through preoperative assessment, considering the medications in use, laboratory and images. An adequate pharmacological management of patients with hypertension in the perioperative period will prevent cardiovascular complications. Therefore the health care team must assure that patients with hypertension will be operated in optimal conditions.


La hipertensión arterial es una enfermedad con alta prevalencia en la población chilena, llegando a casi el 75 por ciento en el grupo de mayores de 65 años. En el ámbito quirúrgico, el número de pacientes de edad mayor y que padecen hipertensión arterial ha aumentado significativamente, lo que nos obliga a realizar una adecuada y detallada evaluación preoperatoria del paciente hipertenso con el fin de conocer su condición al momento de la cirugía, los medicamentos antihipertensivos que utiliza y solicitar los exámenes de laboratorio y/o de imágenes necesarios. Una adecuada asesoría al paciente respecto al manejo de su medicación antihipertensiva preoperatoria pretende disminuir las complicaciones en todo el período perioperatorio, tanto por su suspensión como por su mantención. De esta forma se busca establecer las medidas que permitan al paciente enfrentar el procedimiento quirúrgico en las mejores condiciones posibles.


Subject(s)
Humans , Adrenergic beta-Antagonists/administration & dosage , Antihypertensive Agents/administration & dosage , Calcium Channel Blockers/administration & dosage , Hypertension/prevention & control , Angiotensin-Converting Enzyme Inhibitors/administration & dosage , Surgical Procedures, Operative/methods , Intraoperative Complications/prevention & control , Postoperative Complications/prevention & control , Diuretics/administration & dosage , Hypertension/drug therapy , Preoperative Period
15.
Rev. Soc. Cardiol. Estado de Säo Paulo ; 23(1): 44-55, jan.-mar. 2013. ilus
Article in Portuguese | LILACS | ID: lil-686352

ABSTRACT

O tratamento das arritmias cardíacas é prerrogativa do clínico. Quando são diagnosticadas, é o médico assistente quem opta pela forma de tratar o que, na grande maioria dos casos , se baseia na prescrição de fármacos. Os medicamentos são úteis para a reversão de uma crise aguda e também para a prevenção de recorrências, mas não curam o paciente. A necessidade de tratar ou não uma arritmia depende de vários fatores, como a forma de apresentação clínica baseada na qualidade dos sintomas e a presença ou não de uma cardiopatia. Arritmias que causam colapso hemodinâmico estão associadas a elevado risco de complicações, como traumas físico e até parada cardiorespiratória, como acontece com a taquicardia ventricular. O tratamento, muitas vezes não somente com fármacos, deve ser agressivo visando à proteção do paciente. A presença de uma cardiopatia com disfunção ventricular pode tornar uma arritmia potencialmente maligna e o seu tratamento com fármacos envolve-se de alto risco, não somente pela eficácia apenas moderada dos medicamentos disponíveis, como também pelo risco de agravamento da arritmia, efeito conhecido como pró-arritmia. Não se deve transformar o tratamento mais grave do que a próxima arritmia. Com o avanço no conhecimento dos mecanismos de origem e manutenção das arritmias, houve certa redução da importância e da dependência do antiarrítmico no esquema terapêutico, já que outras classes de fármacos mostraram perfil favorável no tratamento, tal como acontece com os betabloqueadores, inibidores da enzima de conversão da angiotensina, espironolactona, estatinas, etc. Neste artigo, serão discutidos aspectos atuais do tratamento farmacológico das arritmias cardíacas.


The treatment of cardiac arrhythmias is a prerogative of the clinician. When they are diagnosed is the physician who chooses the way of dealing with that, in most cases, is based on prescription of antiarrhythmic drugs. The drugs are useful for the reversal of an acute attack and also for the prevention of recurrences, but not to cure the patient. The need to treat an arrhythmia or not depends on several factors, such as clinical presentation based on the quality of symptoms and the presence or absence of heart disease. Hemodynamic collapse caused by arrhythmias are associated with increased risk of complications, including physical trauma and even cardiac arrest as what happens during verntricular tachycardia. Treatment often, not only with drugs, should be aggressive in order to protect the patient. Some types of arrhythmias in the presence of heart disease with left ventricular dysfunctioin can be become a potentially malignant arrhythmia and its treatment with drugs engages high risk, not only for the modest effectiveness of the medications available but also due to the risk of aggravation of arrhythmia, an effect know as proarrhythmia. One should not make the treatment worse than the arrhythmia itself. With the advances in knowledge of the mechanisms of origin and maintenance of arrhythmia, there was some reduction of the importance and reliance on antiarrhytmic agent in the therapeutic regimen, as other classes of drugs showed favorable profile during treatment, as what happens with beta-blockers, angiotensin converting enzyme inhibitors, spironolactone, statins, etc. This paper will discuss current aspects of pharmacological treatment of cardiac arrhythmias.


Subject(s)
Humans , Adrenergic beta-Antagonists/administration & dosage , Adrenergic beta-Antagonists/therapeutic use , Anti-Arrhythmia Agents/administration & dosage , Anti-Arrhythmia Agents/therapeutic use , Arrhythmias, Cardiac/therapy , Calcium Channel Blockers/administration & dosage , Calcium Channel Blockers/therapeutic use , Stroke Volume
16.
An. bras. dermatol ; 86(4): 763-766, jul.-ago. 2011. ilus
Article in Portuguese | LILACS | ID: lil-600622

ABSTRACT

O hemangioma infantil é o tumor mais comum da infância, com grande variabilidade de apresentação clínica. A maioria das lesões regride espontaneamente e o tratamento está indicado para casos específicos que possam gerar ulceração, disfunção ou desfiguração. O tratamento baseia-se, principalmente, no uso de corticosteroides, seja por via sistêmica, tópica ou intralesional. Recentemente, o propranolol foi descrito como nova opção terapêutica para os hemangiomas, com resultados satisfatórios, permanentes e menos efeitos indesejáveis que os corticosteroides. É relatado o caso de uma criança com hemangioma periorbital e frontoparietal extenso, tratado com propranolol.


Infantile hemangioma or hamangioma of infancy is the most common tumor in children, with great variability of presentation. Most cases resolve spontaneously and treatment is usually indicated for specific cases where injury has a high rate of morbidity or disfigurement after regression. The treatment is based on the use of systemic corticosteroids, which can also be used topically or by intralesional injections. Propranolol has been used recently as a new therapeutic option for the treatment of hemangiomas, with satisfactory, permanent results and fewer adverse effects than corticosteroids. This is a report of the case where a child presenting extensive periorbital and frontoparietal hemangioma was treated with propranolol.


Subject(s)
Female , Humans , Infant , Adrenergic beta-Antagonists/administration & dosage , Antineoplastic Agents/administration & dosage , Hemangioma/drug therapy , Propranolol/administration & dosage , Skin Neoplasms/drug therapy , Treatment Outcome
17.
Clinics ; 66(6): 955-957, 2011. tab
Article in English | LILACS | ID: lil-594361

ABSTRACT

OBJECTIVE: To study tremor in patients with X-linked recessive spinobulbar muscular atrophy or Kennedy's disease. METHODS: Ten patients (from 7 families) with a genetic diagnosis of Kennedy's disease were screened for the presence of tremor using a standardized clinical protocol and followed up at a neurology outpatient clinic. All index patients were genotyped and showed an expanded allele in the androgen receptor gene. RESULTS: Mean patient age was 37.6 years and mean number of CAG repeats 47 (44-53). Tremor was present in 8 (80 percent) patients and was predominantly postural hand tremor. Alcohol responsiveness was detected in 7 (88 percent) patients with tremor, who all responded well to treatment with a β-blocker (propranolol). CONCLUSION: Tremor is a common feature in patients with Kennedy's disease and has characteristics similar to those of essential tremor.


Subject(s)
Adult , Humans , Male , Middle Aged , Young Adult , Bulbo-Spinal Atrophy, X-Linked/physiopathology , Tremor/physiopathology , Age of Onset , Adrenergic beta-Antagonists/administration & dosage , Muscle Weakness/physiopathology , Propranolol/administration & dosage , Tremor/drug therapy
18.
Article in English | WPRIM | ID: wpr-225541

ABSTRACT

OBJECTIVE: The purpose of this study is to determine the effects of propranolol on the left ventricular (LV) volume during CT coronary angiography. MATERIALS AND METHODS: The LV volume of 252 normal Chinese subjects (126 subjects with propranolol medication and 126 age- and gender-matched Chinese subjects without medication) was estimated using 64 slices multi-detector CT (MDCT). The heart rate difference was analyzed by the logistic linear regression model with variables that included gender, age, body height, body weight, systolic blood pressure (SBP), diastolic blood pressure (DBP) and the dosage of propranolol. The following global LV functional parameters were calculated: the real-end diastolic volume (EDV), the real-end systolic volume (ESV) and the real-ejection fraction (EF). RESULTS: The female subjects had a greater decrease of heart rate after taking propranolol. The difference of heart rate was negatively correlated with the dosage of propranolol. The real-EDV, the real-ESV and the real-EF ranged from 48.1 to 109 mL/m2, 6.1 to 57.1 mL/m2 and 41% to 88%, respectively. There was no significant difference in the SBP and DBP between the groups without and with propranolol medication (123 +/- 17 and 80 +/- 10 mmHg; 120 +/- 14 and 80 +/- 11 mmHg, respectively). The real-EDV showed no significant difference between these two groups, but the real-ESV and real-EF showed significant differences between these two groups (69.4 +/- 9.3 and 70.6 +/- 8.9 mL/m2; 23.5 +/- 5.7 and 25.6 +/- 3.7 mL/m2, 66.5 +/- 5.1% and 63.5 +/- 4.6%, respectively). CONCLUSION: The difference of heart rate is significantly influenced by gender and the dosage of propranolol. Propranolol will also increase the ESV, which contributes to a decreased EF, while the SBP, DBP and EDV are not statistically changed.


Subject(s)
Adrenergic beta-Antagonists/administration & dosage , Case-Control Studies , China , Contrast Media , Coronary Angiography , Diastole , Electrocardiography , Female , Heart Rate/drug effects , Humans , Logistic Models , Male , Middle Aged , Propranolol/administration & dosage , Radiographic Image Interpretation, Computer-Assisted , Systole , Tomography, X-Ray Computed , Triiodobenzoic Acids , Ventricular Function, Left/drug effects
19.
Rev. chil. pediatr ; 81(6): 523-530, dic. 2010. ilus, tab
Article in Spanish | LILACS | ID: lil-583038

ABSTRACT

Infantile Hemangiomas (IH) are common vascular tumors in children. Only 10-15 percent) should be treated by any vital, functional or aesthetic complications. Oral corticosteroids are the treatment of choice. However, in the last two years an excellent response to treatment of hemangiomas with oral Propranolol has been reported. Objective: evaluate this new therapy in a limited number of chilean patients with IH with an indication of systemic treatment and present this experience. Patients and Methods: We present 30 cases of IH treated at our institution with oral Propranolol, using a dose of 2 mg/kg/day divided in 2 daily doses. Results: 11 percent of patients were female, 40 percent hemangiomas had segmental distribution, 90 percent were solitary, 61 percent were located in the head and neck and 23 percent were ulcerated. The treatment started at an average of 119 days of life and lasted for an average of 7 months. In all our patients the use of Propranolol accelerated the onset of involution of the hemangiomas and decreased color, brightness and growth too. 43 percent of the patients had irritability and sleep disorders. No significant adverse effects were reported in any of our patients. Conclusión: Propranolol treatment was highly effective and safe in our series of patients and we propose, taking into account published reports based on this data, it should become the treatment of choice for IH.


Los Hemangiomas de la Infancia (HI) son tumores vasculares frecuentes en la edad pediátrica. Sólo un 10-15 por cientoo debe ser tratado por eventuales consecuencias vitales, funcionales o estéticas. Los corticoides orales son el tratamiento de elección actual. Sin embargo, en los últimos 2 años se ha reportado la excelente respuesta de los hemangiomas al tratamiento con Propranolol oral. Objetivo: Evaluar esta nueva terapéutica en un número limitado de pacientes Chilenos con hemangiomas de la infancia con indicación de tratamiento sistémico y presentar esta experiencia. Pacientes y Método: Presentamos 30 casos de HI tratados en nuestra institución con Propranolol oral, usando una dosis de 2 mg/kg/día en 2 tomas diarias. Resultados: Un 77 por ciento de los pacientes eran de sexo femenino. El 40 por ciento de los hemangiomas eran segmentarios, 90 por ciento eran únicos, 67 por ciento estaban ubicados en cabeza y cuello y 23 por ciento estaban ulcerados. El tratamiento se inició en promedio a los 119 días de vida y duró en promedio 7 meses. En la totalidad de nuestros pacientes el uso de Propranolol aceleró el inicio de la involución del hemangioma y disminuyó el color, brillo y crecimiento. El 43 por ciento de los pacientes presentó irritabilidad y trastornos del sueño. No se presentaron efectos adversos importantes en ninguno de nuestros pacientes. Conclusión: El tratamiento con Propranolol fue altamente efectivo y seguro en nuestra serie de pacientes y proponemos, tomando en cuenta los reportes publicados al respecto, que debiera ser el tratamiento de elección para los hemangiomas de la infancia.


Subject(s)
Humans , Male , Female , Child , Adrenergic beta-Antagonists/therapeutic use , Hemangioma/drug therapy , Skin Neoplasms/drug therapy , Thoracic Neoplasms/drug therapy , Head and Neck Neoplasms/drug therapy , Propranolol/therapeutic use , Administration, Oral , Adrenergic beta-Antagonists/administration & dosage , Propranolol/administration & dosage , Treatment Outcome
20.
Arq. bras. cardiol ; 95(4): 530-535, out. 2010. tab
Article in Portuguese | LILACS | ID: lil-568964

ABSTRACT

FUNDAMENTO: Há evidências de que a suspensão do betabloqueador (BB) na descompensação cardíaca pode aumentar mortalidade. A dobutamina (dobuta) é o inotrópico mais utilizado na descompensação, no entanto, BB e dobuta atuam no mesmo receptor com ações antagônicas, e o uso concomitante dos dois fármacos poderia dificultar a compensação. OBJETIVO: Avaliar se a manutenção do BB associado à dobuta dificulta a compensação cardíaca. MÉTODOS: Estudados 44 pacientes com FEVE < 45 por cento e necessidade de inotrópico. Divididos em três grupos de acordo com o uso de BB. Grupo A (n=8): os que não usavam BB na admissão; Grupo B (n=25): os que usavam BB, porém foi suspenso para iniciar a dobuta; Grupo C (n=11): os que usaram BB concomitante à dobuta. Para comparação dos grupos, foram utilizados os testes t de Student, exato de Fisher e qui-quadrado. Considerado significante p < 0,05. RESULTADOS: FEVE média de 23,8 ± 6,6 por cento. O tempo médio do uso de dobuta foi semelhante nos três grupos (p=0,35), e o uso concomitante da dobuta com o BB não aumentou o tempo de internação (com BB 20,36 ± 11,04 dias vs sem BB 28,37 ± 12,76 dias, p=NS). Na alta, a dose do BB foi superior nos pacientes em que a medicação não foi suspensa (35,8 ± 16,8 mg/dia vs 23,0 ± 16,7 mg/dia, p=0,004). CONCLUSÃO: A manutenção do BB associado à dobuta não aumentou o tempo de internação e não foi acompanhada de pior evolução. Os pacientes que não suspenderam o BB tiveram alta com doses mais elevadas do medicamento.


BACKGROUND: There is evidence that the suspension of betablockers (BB) in decompensated heart failure may increase mortality. Dobutamine (dobuta) is the most commonly used inotrope in decompensation, however, BB and dobuta act with the same receptor with antagonist actions, and concurrent use of both drugs could hinder compensation. OBJECTIVE: To evaluate whether the maintenance of BB associated with dobuta difficults cardiac compensation. METHODS: We studied 44 patients with LVEF < 45 percent and the need for inotropics. Divided into three groups according to the use of BB. Group A (n=8): those who were not using BB at baseline; Group B (n=25): those who used BB, but was suspended to start dobuta; Group C (n = 11): those who used BB concomitant to dobuta. To compare groups, we used the Student t, Fisher exact and chi-square tests. Considered significant if p < 0.05. RESULTS: Mean LVEF 23.8 ± 6.6 percent. The average use of dobuta use was similar in all groups (p = 0.35), and concomitant use of dobutamine with BB did not increase the length of stay (BB 20.36 ± 11.04 days vs without BB 28.37 ± 12.76 days, p = NS). In the high dose, BB was higher in patients whose medication was not suspended (35.8 ± 16.8 mg/day vs 23.0 ± 16.7 mg/day, p = 0.004). CONCLUSION: Maintaining BB associated with dobutamine did not increase the length of hospitalization and was not associated with the worst outcome. Patients who did not suspend BB were discharged with higher doses of the drug.


FUNDAMENTO: Hay evidencias de que la suspensión del betabloqueante (BB) en la descompensación cardíaca puede aumentar la mortalidad. La dobutamina (dobuta) es el inotrópico más utilizado en la descompensación, mientras tanto, BB y dobuta actúan en el mismo receptor con acciones antagónicas, y el uso concomitante de los dos fármacos podría dificultar la compensación. OBJETIVO: Evaluar si la manutención del BB asociado a la dobuta dificulta la compensación cardíaca. MÉTODOS: Estudiados 44 pacientes con FEVI < 45 por ciento y necesidad de inotrópico. Divididos en tres grupos de acuerdo con el uso de BB. Grupo A (n=8): los que no usaban BB en la admisión; Grupo B (n=25): los que usaban BB, sin embargo fue suspendido para iniciar la dobuta; Grupo C (n=11): los que usaron BB concomitantemente a la dobuta. Para comparación de los grupos, fueron utilizados los test t de Student, exacto de Fisher y qui-cuadrado. Considerado significante P < 0,05. RESULTADOS: FEVI media de 23,8±6,6 por ciento. El tiempo medio de uso de dobuta fue semejante en los tres grupos (p=0,35), y el uso concomitante de la dobuta con el BB no aumentó el tiempo de internación (con BB 20,36 ± 11,04 días vs sin BB 28,37 ± 12,76 días, p=NS). En el alta, la dosis del BB fue superior en los pacientes en que la medicación no fue suspendida (35,8 ± 16,8 mg/día vs 23,0 ± 16,7 mg/día, p=0,004). CONCLUSIÓN: La manutención del BB asociado a la dobuta no aumentó el tiempo de internación y no fue acompañada de peor evolución. Los pacientes que no suspendieron el BB tuvieron alta con dosis más elevadas del medicamento.


Subject(s)
Female , Humans , Male , Middle Aged , Adrenergic beta-Antagonists/adverse effects , Cardiotonic Agents/therapeutic use , Dobutamine/therapeutic use , Heart Failure/drug therapy , Withholding Treatment , Adrenergic beta-Antagonists/administration & dosage , Adrenergic beta-Antagonists/metabolism , Cardiac Output, Low/complications , Cardiac Output, Low/drug therapy , Drug Therapy, Combination/adverse effects , Length of Stay/statistics & numerical data , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL